Please select the option that best describes you:
Topics:
Radiation Oncology • Palliation
Would you consider spine re-irradiation after Pluvicto?
A patient who previously was treated to 30 Gy in 10 fraction from T2-T4 recently completed Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for progressive metastatic prostate cancer.
Is there any available insight into the risks of re-treatment of the spine in this setting, especially in a patient with > 6-12 month life expectancy, not amenable to kyphoplasty, cryoablation, RFA or surgery given multilevel disease (T1-7)?
Radiation Oncologist
This question will become more common as more patients undergo PSMA-based radiopharmaceutical therapy (RPT). The focus of this question seems to be related to the additional dose to which RPT may expose the cord and the ensuing risk of myelopathy. In summary, I do not believe there is (or could...
Sign in or Register to read more